MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men

被引:16
|
作者
Tan, Teck Wei [1 ]
Png, Keng Siang [1 ]
Lee, Chau Hung [2 ]
Yuwono, Arianto [1 ]
Yeow, Yuyi [1 ]
Chong, Kian Tai [1 ]
Lee, Yee Mun [1 ]
Tan, Cher Heng [2 ]
Tan, Yung Khan [1 ]
机构
[1] Tan Tock Seng Hosp, Dept Urol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
[2] Tan Tock Seng Hosp, Dept Diagnost Radiol, Singapore, Singapore
关键词
MRI fusion; prostate cancer; targeted biopsy; PI-RADS; PHI; PSAD; RESONANCE-IMAGING MRI; MULTI-PARAMETRIC MRI; PREDICTIVE-VALUE; VERSION; GUIDELINES; DIAGNOSIS; SYSTEM;
D O I
10.1089/end.2017.0485
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To test the hypothesis that targeted biopsy has a higher detection rate for clinically significant prostate cancer (csPCa) than systematic biopsy. We defined csPCa as any Gleason sum 7 cancer. In patients with Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, to determine if factors, such as prostate-specific antigen density (PSAD) and prostate health index (PHI), can predict csPCa and help select patients for biopsy. Materials and Methods: We report the first series of targeted biopsies in Southeast Asian men, with comparison against systematic biopsy. Consecutive patients were registered into a prospective institutional review board-approved database in our institution. We reviewed patients who underwent biopsy from May 2016 to June 2017. Inclusion criteria for our study were patients with at least one PI-RADS 3, and who underwent both targeted and systematic biopsies in the same sitting. Results: There were 115 patients in the study, of whom 74 (64.3%) had a previous negative systematic biopsy. Targeted biopsies detected significantly less Gleason 6 cancers than systematic biopsies (p<0.01), and demonstrated significantly higher sensitivity, specificity, positive predictive value, and negative predictive value (NPV) for the detection of csPCa. For patients with PI-RADS 3 lesions, PHI and PSAD were found to be the best predictors for csPCa. PSAD <0.10ng/mL/mL had an NPV of 93% and sensitivity of 92%, while allowing 20% of patients to avoid biopsy. PHI cutoff of <27 would allow 34% of patients to avoid biopsy, with both sensitivity and NPV of 100%. Conclusions: Targeted prostate biopsies were found to be significantly superior to systematic biopsies for the detection of csPCa, while detecting less Gleason 6 cancer. Usage of PSAD and PHI cutoff levels in patients with PI-RADS 3 lesions may enable a number of patients to avoid unnecessary biopsy.
引用
收藏
页码:1111 / 1116
页数:6
相关论文
共 50 条
  • [1] Utility of MRI fusion-targeted transrectal prostate biopsy and prostate health index in detection of clinically significant prostate cancer
    Leow, J.
    Yeow, Y.
    Tan, T.
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 84 - 85
  • [2] Utility of MRI fusion-targeted transrectal prostate biopsy and prostate health index detection of clinically significant prostate cancer
    Yeow, Y.
    Leow, J.
    Tan, T. W.
    [J]. BJU INTERNATIONAL, 2019, 123 : 31 - 31
  • [3] Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels
    Seokhwan Bang
    Jiwoong Yu
    Jae Hoon Chung
    Wan Song
    Minyong Kang
    Hyun Hwan Sung
    Hwang Gyun Jeon
    Byong Chang Jeong
    Seong Il Seo
    Hyun Moo Lee
    Seong Soo Jeon
    [J]. Scientific Reports, 11
  • [4] Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels
    Bang, Seokhwan
    Yu, Jiwoong
    Chung, Jae Hoon
    Song, Wan
    Kang, Minyong
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Lee, Hyun Moo
    Jeon, Seong Soo
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection
    Chiu, Shih-Ting
    Cheng, Yung-Ting
    Pu, Yeong-Shiau
    Lu, Yu-Chuan
    Hong, Jian-Hua
    Chung, Shiu-Dong
    Chiang, Chih-Hung
    Huang, Chao-Yuan
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] Diagnostic performance of targeted transrectal MRI-Ultrasound fusion prostate biopsy in detecting clinically significant prostate cancer
    Yuwono, A.
    Tan, T. -W.
    Yeow, Y.
    Lee, C. -H.
    Tan, C. -H.
    Chong, K. -T.
    Lee, Y. -M.
    Png, K. -S.
    Tan, Y. -K.
    [J]. BJU INTERNATIONAL, 2017, 119 : 19 - 19
  • [7] Value of Prostate-Specific Antigen and Prostate-Specific Antigen Density in Detection of Prostate Cancer in an Iranian Population of Men
    Ghafoori, Mahyar
    Varedi, Peyman
    Hosseini, Seyed Jalil
    Asgari, Mojgan
    Shakiba, Madjid
    [J]. UROLOGY JOURNAL, 2009, 6 (03) : 182 - 188
  • [8] PROSTATE-SPECIFIC ANTIGEN AND TRANSRECTAL ULTRASOUND OF THE PROSTATE IN DETECTION OF PROSTATE-CANCER
    COONER, WH
    [J]. CLINICAL AND INVESTIGATIVE MEDICINE, 1993, 16 (06): : 471 - 474
  • [9] The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men <= 50 years
    Kosaka, Takeo
    Mizuno, Ryuichi
    Shinojima, Toshiaki
    Miyajima, Akira
    Kikuchi, Eiji
    Tanaka, Nobuyuki
    Shinoda, Kazunobu
    Morita, Shinya
    Mikami, Shuji
    Oya, Mototsugu
    [J]. AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2014, 2 (04): : 332 - 336
  • [10] Comparison of Prostate-Specific Antigen and Its Density and Prostate Health Index and Its Density for Detection of Prostate Cancer
    Boo, Youngjun
    Chung, Jae Hoon
    Kang, Minyong
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Song, Wan
    [J]. BIOMEDICINES, 2023, 11 (07)